Health CarePharmaceuticals & Biotechnology
  • Price (USD)51.80
  • Today's Change0.12 / 0.23%
  • Shares traded2.37m
  • 1 Year change9.82%
  • Beta0.9947
Data delayed at least 15 minutes, as of Jul 03 2020 00:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Cardinal Health, Inc. is a healthcare services and products company. The Company operates through two segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products. This segment also operates nuclear pharmacies and cyclotron facilities; provides pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers, and provides services to healthcare companies. The Medical segment distributes a range of medical, surgical and laboratory products, and provides services to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers. This segment also manufactures, sources and develops its own Cardinal Health brand medical and surgical products. It provides post-acute care management and transition services, and software to hospitals.

  • Revenue in USD (TTM)153.59bn
  • Net income in USD-4.16bn
  • Incorporated1979
  • Employees49.50k
  • Location
    Cardinal Health Inc7000 Cardinal PlDUBLIN 43017-1091United StatesUSA
  • Phone+1 (614) 757-3033
  • Fax+1 (614) 757-6000
  • Websitehttps://www.cardinalhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
10X Genomics Inc264.22m-48.76m8.85bn584.00--21.59--33.50-0.5085-0.50852.764.17------452,431.50--------76.47---18.45--6.95--0.00--68.06--72.22------
PPD Inc4.14bn63.36m9.37bn23.00k145.92--28.882.260.18420.184212.10-3.10----------------40.05--1.42----1.461.31--7.52---43.25------
Quidel Corporation561.58m88.31m9.54bn1.25k110.8615.7567.8116.982.052.0513.1114.410.59983.466.55449,260.009.433.7011.204.2861.4160.1015.736.911.679.520.02070.002.4123.77-1.70--19.36--
BIO-TECHNE Corp754.52m186.91m10.29bn2.25k56.847.9538.3113.644.744.7419.1833.870.38982.656.00335,343.109.667.1110.197.5266.0267.0124.7716.623.748.330.245450.0211.0414.823.36-2.8412.950.8001
Horizon Therapeutics PLC1.38bn592.29m10.54bn1.19k19.494.8112.607.662.832.837.0011.480.33356.083.321,146,306.0014.36-0.344417.52-0.410473.0064.9543.06-
Neurocrine Biosciences, Inc.886.78m176.53m11.64bn700.0068.2616.6163.1013.131.841.849.217.550.76460.4918.041,266,834.0015.22-9.1816.75-10.7199.05--19.91-21.906.756.190.3716--74.65--75.32--55.69--
Catalent Inc2.87bn109.80m11.84bn12.30k97.935.1533.664.120.74280.742819.2918.040.49646.824.36233,528.502.383.692.724.2231.5131.814.796.471.552.050.53370.002.226.628.8748.7012.25--
Sarepta Therapeutics Inc407.50m-655.92m12.69bn743.00--11.08--31.15-8.83-8.835.4514.690.16590.36445.18548,446.80-26.71-34.31-29.36-38.8685.98---160.96-191.557.75-49.140.3754--26.51108.11-97.58--18.51--
EXACT Sciences Corporation1.06bn-106.63m12.99bn4.11k--5.10--12.23-0.7663-0.76637.7716.980.34094.4910.83258,411.40-3.42-14.64-3.66-15.9375.9872.26-10.04-40.255.81-5.540.3775--92.82244.8052.04--70.67--
Cardinal Health Inc153.59bn-4.16bn15.12bn49.50k--12.57--0.0985-14.04-14.04519.754.123.7511.5318.183,102,748.00-10.142.60-24.916.024.535.16-2.710.72680.52867.550.857659.416.389.83300.443.225.679.50
Alnylam Pharmaceuticals, Inc.285.93m-886.42m17.21bn1.32k--12.57--60.18-8.03-8.032.5911.930.13320.69825.23216,124.00-41.29-35.69-46.58-39.3687.75---310.01-600.534.48--0.00--193.3634.16-16.24--32.78--
AmerisourceBergen Corp.186.16bn1.58bn20.36bn22.00k13.185.6710.060.10947.597.59886.8517.664.6016.1112.978,461,793.003.942.1116.508.732.782.780.85520.44350.625315.640.52843.626.948.48-21.7523.773.2411.22
Data as of Jul 03 2020. Currency figures normalised to Cardinal Health Inc's reporting currency: US Dollar USD

Institutional shareholders

40.11%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202035.14m12.04%
SSgA Funds Management, Inc.as of 31 Mar 202020.00m6.85%
BlackRock Fund Advisorsas of 31 Mar 202015.71m5.38%
Macquarie Investment Management Business Trustas of 31 Mar 202013.70m4.69%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20208.31m2.85%
Mellon Investments Corp.as of 31 Mar 20205.70m1.95%
Geode Capital Management LLCas of 31 Mar 20205.02m1.72%
SunAmerica Asset Management LLCas of 31 Mar 20204.85m1.66%
Fidelity Management & Research Co. LLCas of 31 Mar 20204.46m1.53%
American Century Investment Management, Inc.as of 31 Mar 20204.23m1.45%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.